Temapharm

Temapharm is a Polish biotechnology company specializing in the research and development of innovative small molecule therapeutics. Based in Warsaw, the company focuses on medicinal chemistry and preclinical development to address unmet needs in oncology and inflammatory diseases. Its lead candidate, TMP-001, is an original small molecule being developed for the topical treatment of psoriasis and has progressed into early clinical evaluation. Temapharm leverages a network of academic collaborations and national research funding to advance its pipeline of proprietary drug candidates. The company aims to provide effective and safe therapeutic alternatives for patients with chronic dermatological and cancerous conditions.